Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
Expert Ratings for Incyte
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
New Indication Approval For Incyte “To Usher New Growth Avenue”
JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ:INCY) based on…
SVB Leerink Maintains Underperform on Incyte, Raises Price Target to $63
SVB Leerink analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Underperform and raises the price target from $58 to $63.
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Twitter And 3 Other Stocks Insiders Are Selling
US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
CHMP Backs Approval of Lilly/Incyte’s Olumiant For Patchy Hair Loss
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly…